Adverse events during testosterone replacement therapy in 95 young hypogonadal thalassemic men.

Background: Hormonal treatment of hypogonadism in thalassaemia major (TM) is a complex issue due to the co-existence of other contributing factors such as severity of iron overload, associated chronic liver disease and other endocrine complications.